Volatile anesthetics inhibit mammalian voltage-gated Na ϩ channels, an action that contributes to their presynaptic inhibition of neurotransmitter release. We measured the effects of isoflurane, a prototypical halogenated ether volatile anesthetic, on the prokaryotic voltage-gated Na ϩ channel from Bacillus halodurans (NaChBac). Using whole-cell patch-clamp recording, human embryonic kidney 293 cells transfected with NaChBac displayed large inward currents (I Na ) that activated at potentials of Ϫ60 mV or higher with a peak voltage of activation of 0 mV (from a holding potential of Ϫ80 mV) or Ϫ10 mV (from a holding potential of Ϫ100 mV). Isoflurane inhibited I Na in a concentration-dependent manner over a clinically relevant concentration range; inhibition was significantly more potent from a holding potential of Ϫ80 mV (IC 50 ϭ 0.35 mM) than from Ϫ100 mV (IC 50 ϭ 0.48 mM). Isoflurane positively shifted the voltage dependence of peak activation, and it negatively shifted the voltage dependence of end steady-state activation. The voltage dependence of inactivation was negatively shifted with no change in slope factor. Enhanced inactivation of I Na was 8-fold more sensitive to isoflurane than reduction of channel opening. In addition to tonic block of closed and/or open channels, isoflurane enhanced use-dependent block by delaying recovery from inactivation. These results indicate that a prokaryotic voltage-gated Na ϩ channel, like mammalian voltage-gated Na ϩ channels, is inhibited by clinical concentrations of isoflurane involving multiple state-dependent mechanisms. NaChBac should provide a useful model for structure-function studies of volatile anesthetic actions on voltage-gated ion channels.
channels, an action that contributes to their presynaptic inhibition of neurotransmitter release. We measured the effects of isoflurane, a prototypical halogenated ether volatile anesthetic, on the prokaryotic voltage-gated Na ϩ channel from Bacillus halodurans (NaChBac). Using whole-cell patch-clamp recording, human embryonic kidney 293 cells transfected with NaChBac displayed large inward currents (I Na ) that activated at potentials of Ϫ60 mV or higher with a peak voltage of activation of 0 mV (from a holding potential of Ϫ80 mV) or Ϫ10 mV (from a holding potential of Ϫ100 mV). Isoflurane inhibited I Na in a concentration-dependent manner over a clinically relevant concentration range; inhibition was significantly more potent from a holding potential of Ϫ80 mV (IC 50 ϭ 0.35 mM) than from Ϫ100 mV (IC 50 ϭ 0.48 mM). Isoflurane positively shifted the voltage dependence of peak activation, and it negatively shifted the voltage dependence of end steady-state activation. The voltage dependence of inactivation was negatively shifted with no change in slope factor. Enhanced inactivation of I Na was 8-fold more sensitive to isoflurane than reduction of channel opening. In addition to tonic block of closed and/or open channels, isoflurane enhanced use-dependent block by delaying recovery from inactivation. These results indicate that a prokaryotic voltage-gated Na ϩ channel, like mammalian voltage-gated Na ϩ channels, is inhibited by clinical concentrations of isoflurane involving multiple state-dependent mechanisms. NaChBac should provide a useful model for structure-function studies of volatile anesthetic actions on voltage-gated ion channels.
Despite significant recent advances, the mechanisms of volatile anesthetic action are still poorly understood . Recent evidence implicates mammalian voltage-gated Na ϩ channels (Na v ) as targets for the presynaptic depression of neurotransmitter release by volatile anesthetics (Ouyang et al., 2003 (Ouyang et al., , 2005 Wu et al., 2004; Hemmings et al., 2005) . Voltage-gated Na ϩ channels are critical for the initiation and conduction of action potentials in excitable cells (Hodgkin and Huxley, 1952; Hille, 2001) , and they are important in regulating presynaptic excitability (Meir et al., 1999) and neurotransmitter release (Tibbs et al., 1989) . Nine homologous subtypes of the four-domain pore-forming Na v ␣ subunit have been identified in mammals (Yu and Catterall, 2003) . A single-domain prokaryotic voltage-gated Na ϩ channel (NaChBac) with similar properties to mammalian voltage-gated ion channels has been isolated from Bacillus halodurans (Ren et al., 2001) . The single domain of the presumably tetrameric NaChBac consists of six transmembrane ␣-helical segments structurally homologous to the six transmembrane segments of each of the four domains of voltage-gated Na ϩ and Ca 2ϩ channels. NaChBac exhibits the basic kinetic features of Na v : it opens with depolarization in a voltage-dependent manner (activation) over a comparable voltage range; closes upon prolonged depolarization (inactivation); and returns to a resting, nonconducting state with repolarization (deactivation) (Ren et al., 2001 ). However, the kinetic behavior of NaChBac is slower than that of eukaryotic Na v channels, including ϳ6-fold slower activation, ϳ17-fold slower inactivation, and ϳ10-fold slower recovery from inactivation (Ren et al., 2001; Kuzmenkin et al., 2004) . These conserved basic gating mechanisms with slower kinetics provide a potential advantage in studying NaChBac as a model for Na v because of the intrinsic demands of doing experiments with channels that have substantially faster gating. NaChBac activation is preceded by movement of a gating charge, an essential feature of voltage-gated ion channels (Kuzmenkin et al., 2004) . The relatively simple amino acid sequence of NaChBac (274 amino acids; 31 kDa), its structural homology to Na v , and the ease of producing large amounts in bacterial culture provide a potential opportunity for structure-function studies and three-dimensional structure determinations by X-ray crystallography of a model anesthetic target. This led us to investigate the effects of isoflurane, a prototypical inhaled anesthetic ether, on the basic functional properties of heterologously expressed NaChBac. Isoflurane is representative of the modern family of halogenated ether anesthetics currently in widespread clinical use that are thought to share their essential molecular targets for the production of general anesthesia .
Materials and Methods
Heterologous Expression of NaChBac. The cDNA for wildtype NaChBac in a modified pTracer expression vector (6.2 kilobases, containing green fluorescent protein-Zeocin site; Invitrogen, Carlsbad, CA), generously provided by Dr. D. Clapham (Harvard University, Boston, MA), was amplified in bacterial culture, and then the cDNA was purified. HEK 293 cells (American Type Culture Collection, Manassas, VA) were transiently transfected using Lipofectamine 2000 (Invitrogen) and cultured in Dulbecco's modified Eagle's medium/F-12 (Invitrogen) with 5% (v/v) fetal bovine serum (BioSource International, Camarillo, CA) and 5% CO 2 , 95% O 2 (v/v) at 37°C. One to 3 days before electrophysiological recording, cells were plated on glass coverslips in 35-mm plastic dishes (BD Biosciences, Franklin Lakes, NJ). Transfected cells were identified using a Nikon ECLIPSE TE300 inverted fluorescence microscope (Nikon, Melville, NY).
Electrophysiological Recordings. The culture medium was changed, and cells were superfused at 2 to 3 ml/min with extracellular solution containing 140 mM NaCl, 4 mM KCl, 1.5 mM CaCl 2 , 1.5 mM MgCl 2 , 10 mM HEPES, and 5 mM D-glucose, pH 7.30 with NaOH. Na ϩ currents (I NaChBac ) were recorded at room temperature (24 -26°C) using the whole-cell patch-clamp technique (Hamill et al., 1981) . Patch electrodes were made from borosilicate glass capillaries (Drummond Scientific, Broomall, PA) using a four-step protocol (P-97 micropipette puller; Sutter Instrument Company, Novato, CA), fire polished (Narishige Microforge, Kyoto, Japan) and coated with SYLGARD (Dow Corning, Midland, MI) to reduce background noise and capacitance. The pipette electrode solution contained 80 mM CsF, 40 mM CsCl, 15 mM NaCl, 10 mM HEPES, and 10 mM EGTA, pH 7.35 with CsOH. Cells Ͻ15 m in diameter were selected for recording using low resistance electrodes (1-3 M⍀). To determine the contribution of steady-state inactivation to isoflurane inhibition I NaChBac , two holding potentials (Ϫ80 or Ϫ100 mV) were used. Because of the slow current decay observed with consecutive pulses, low-frequency stimuli (0.2 or 2 Hz) were used to study use-dependent block of I Na . Currents were sampled at 10 or 20 kHz and filtered at 1 to 3 kHz using an Axon 200B amplifier, digitized with a Digidata 1321A interface, and analyzed using pClamp 8.2 software (Molecular Devices, Sunnyvale, CA). Capacitance and 60 and 85% series resistance were compensated, and leak current was subtracted using P/4 or P/5 protocols. Cells were held at Ϫ80 mV between recordings with pulse frequencies of 0.1 to 2 Hz.
Isoflurane (Abbott Laboratories, North Chicago, IL) was diluted from stock solutions in 10 to 12 mM extracellular solution (prepared by stirring at room temperature for 12-24 h) into airtight glass syringes. It was applied locally to attached cells at 0.05 ml/min through a 0.15-mm-diameter perfusion pipette located 30 to 40 m from patched cells using an ALA-VM8 pressurized perfusion system (ALA Scientific Instruments, Westbury, NY). Isoflurane concentrations were determined by local sampling of the perfusate at the site of the recording pipette tip and by analysis by gas chromatography following n-heptane extraction; measured isoflurane concentrations were ϳ85% of syringe concentrations.
Data Analysis. IC 50 values (Ϯ S.E.M.) for isoflurane were determined by least-squares fitting of data to the Hill equation: I Na /I Na Control ϭ 1/(1 ϩ 10ˆ((log IC 50 Ϫ X) ϫ n H )), where X is isoflurane concentration, I Na /I Na Control is normalized Na ϩ current, and n H is Hill slope. Normalized activation data were fitted to a Boltzmann equation: G/G max ϭ 1/(1 ϩ exp(V 1/2a Ϫ V)/k), where G/G max is normalized fractional conductance, G max is maximal conductance, V 1/2a is voltage for half-maximal activation, and k is slope factor. Na ϩ conductance (G Na ) was calculated as G Na ϭ I Na /(V t Ϫ V r ), where I Na is peak Na ϩ current, V t is test potential, and V r is Na ϩ reversal potential (E Na ϭ 67 mV). Inactivation curves were fitted to a Boltzmann equation: I Na /I Na max ϭ 1/(1 ϩ exp(V Ϫ V 1/2in )/k), where I Na / I Na max is normalized current, I Na max is maximal current, V 1/2in is voltage of half-maximal inactivation, V is test potential, and k is slope factor. I Na inactivation was analyzed by fitting to a monoexponential equation: I Na ϭ A⅐exp(Ϫt/) ϩ C, where A is maximal I Na amplitude, C is plateau I Na , t is time, and is the time constant of current decay. NaChBac current traces were also fitted to the conventional Hodgkin and Huxley m 3 h model (Hodgkin and Huxley 1952) in modified form:
, where I(t) is I Na as a function of time, I o is I Na at t ϭ t o , I max is maximal current, t o is initial time of I Na rising phase, t is time during the pulse, and act and inact are activation and inactivation time constants, respectively. The time course of usedependent decay of I Na was analyzed by fitting to a monoexponential equation: Normalized I Na ϭ exp(Ϫtime constant ϫ t) ϩ C, t is pulse number, C is plateau I Na , and time constant is the time constant of use dependent of decay. Data were analyzed using pCLAMP 8.2, Prism version 4.0 (GraphPad Software Inc., San Diego, CA), SigmaPlot version 9.0 (Systat Software, Inc., San Jose, CA), and Origin 7.5 SR4 (OriginLab Corp., Northampton, MA). Statistical significance (p Ͻ 0.05) was assessed by analysis of variance or paired t test, as indicated.
Results
Basic Properties of NaChBac. HEK 293 cells expressing NaChBac showed voltage-gated I Na up to 10 nA ( Fig. 1) . Cells with endogenous Na ϩ currents (amplitude Ͻ0.25 Ϯ 0.08 nA; n ϭ 8), easily identified by their faster activation compared with I Na , were discarded. To avoid large series resistance and space-clamp error, only cells with I Na of 0.5 to 5 nA were analyzed. I Na activated at Ϫ60 mV or higher. Peak activation was at 0 mV from a holding potential of Ϫ80 mV, and at Ϫ10 mV from a holding potential of Ϫ100 mV, where a large fraction of channels are available and in the resting state (Ren et al., 2001; Fig. 1B) . Peak I Na occurred 10 to 20 ms from the beginning of the depolarizing pulse, which is consistent with a report that NaChBac activation is severalfold slower compared with Na v (Ren et al., 2001) . I Na reversed at ϩ70 mV (Fig. 1B) , near the calculated Nernst equilibrium potential for Na ϩ for the conditions used (ϩ67 mV). I Na inactivation developed over 700 to 850 ms (Fig. 2) .
Isoflurane Inhibits NaChBac. Isoflurane reversibly inhibited I Na with no change in the voltage of peak activation or reversal potential (Figs. 1 and 2). The effects of isoflurane on I Na were similar from a holding potential of Ϫ80 or Ϫ100 mV. The concentration-effect curves were well fitted by the Hill equation (Fig. 2B) , and they yielded IC 50 values near the clinically effective concentration of isoflurane (aqueous concentration equivalent to minimal alveolar concentration ϭ 0.35 mM in rat; Taheri et al., 1991): 0.35 Ϯ 0.03 mM from a Isoflurane Inhibits NaChBac holding potential of Ϫ80 mV and 0.48 Ϯ 0.02 mM from a holding potential of Ϫ100 mV (p Ͻ 0.01; n ϭ 4 -12).
Onset of inhibition of I Na by local pipette application of isoflurane was rapid (Ͻ1 min) and reversed within minutes of washout (Fig. 3) . Inactivation of I Na was highly sensitive to isoflurane ( Figs. 2A and 3) . Inactivation was best fitted by a monoexponential function with a time constant () that was markedly reduced by isoflurane, consistent with facilitation of the inactivation process (see below). Isoflurane binding affinity during channel inactivation (K D ϭ 0.06 mM; Fig. 2C ) was 8-fold higher than the IC 50 for peak current amplitude (IC 50 ϭ 0.48 Ϯ 0.02 mM, from a holding of Ϫ100 mV; Fig. 2B ), which reflects binding affinity to open channels. The marked reversible increase in current decay induced by isoflurane was also observed with repetitive stimulation (Fig. 3C ). The linear relationship between blocking rate (1/) and isoflurane concentration (Fig. 2C ) reflects a bimolecular interaction between isoflurane and its binding site (Ramos and O'Leary, 2004) .
Effects of Isoflurane on Channel Gating. The effects of isoflurane on NaChBac channel gating kinetics were analyzed from the calculated conductance and conductance ratios at each of two points (peak and end) during a 30-ms depolarizing pulse (Fig. 4) . Conductance and normalized conductance activation data were best fitted by a simple Boltzmann function. Inhibition at peak current and at the end of the depolarizing pulse more accurately reflect channel kinetic changes induced by isoflurane (see Figs. 1 and 4A ). Isoflurane (ϳ0.8 mM) produced a depolarizing shift in the voltage dependence of peak I Na activation and a hyperpolarizing shift in the voltage dependence of end I Na activation ( Fig. 4B ; Table 1 ). The shift in voltage of end steady-state current activation (V 1/2aend ) by isoflurane was greater from a holding potential of Ϫ100 mV and of voltage of half-maximal peak current (V 1/2apeak ) from Ϫ80 mV (Table 1) . This could be due to a greater fraction of inactivated channels at a holding potential of Ϫ80 mV (Fig. 5) and to more newly inactivated Fig. 1 . Effects of isoflurane on NaChBac current-voltage relationships. A, isoflurane (ϳ0.8 mM; equivalent to ϳ2.3 times minimal alveolar concentration in rat) significantly inhibited I Na from a holding potential of either Ϫ80 or Ϫ100 mV. Effects were analyzed at various phases of the test pulse: 5 ms after depolarization (A), peak I Na at 10 to 20 ms (B), end I Na 29 ms after depolarization (C), and tail current at repolarization (D). B, voltage for peak inward current (V max ) was 0 mV from a holding potential of Ϫ80 mV (left) and Ϫ10 mV from a holding potential of Ϫ100 mV (right). I Na was activated by 30-ms test pulses of Ϫ60 to ϩ70 mV in 10-mV steps. Mean isoflurane concentrations in B were 0.79 Ϯ 0.06 mM for holding potential of Ϫ80 mV and 0.82 Ϯ 0.05 mM for holding potential of Ϫ100 mV (mean Ϯ S.E.M.; n ϭ 7-8).
Fig. 2.
Isoflurane reversibly inhibits NaChBac at clinically relevant concentrations. A, representative current traces showing reversible inhibition by isoflurane of I Na from a holding potential of Ϫ100 mV. B, concentration-effect curves for inhibition of normalized peak I Na by isoflurane from holding potentials of Ϫ80 or Ϫ100 mV. Data (mean Ϯ S.E.M.; n ϭ 4 -12) were fitted to the Hill equation. ‫,ءء‬ p Ͻ 0.01 by Student unpaired t test. C, isoflurane-facilitated current decay was fitted to a monoexponential equation (see Materials and Methods). The blocking rate (1/ ⅐ 1000) plotted against isoflurane concentration was fitted to a linear equation to yield the isoflurane binding affinity (K D ϭ k off /k on ϭ 0.06 mM); the slope and y-intercept yielded the association rate (k on ϭ 98.4 s Ϫ1 mM Ϫ1 ) and dissociation rate (k off ϭ 5.5 s Ϫ1 ), respectively. Currents were evoked by 850 ms test pulses to V max (Ϫ20 to 0 mV). channels at the end of the pulse at a holding potential of Ϫ100 mV, respectively. The net effect of isoflurane was to narrow the current window of activation for either holding potential, thus decreasing the peak current.
Isoflurane reduced channel availability as reflected in the marked hyperpolarizing shift in the voltage dependence of inactivation from a holding potential of Ϫ80 mV with no change in slope factor ( Fig. 5 ; Table 1 ). With a 2-s prepulse from Ϫ80 mV, ϳ26% of channels were inactivated, consistent with greater isoflurane effect early (5 ms; data not shown) in the depolarizing pulse. From a holding potential of Ϫ100 mV, greater block of I Na by isoflurane occurred later in the depolarizing pulse (end of pulse at 29 ms; Table 1 ) due to greater current decay from enhanced channel inactivation.
The effects of isoflurane on NaChBac channel gating were also modeled by fitting to Hodgkin and Huxley m 3 h kinetics. This approach provides only a phenomenological description, but it is useful in evaluating relative effects on activation and inactivation kinetics. Increasing isoflurane shifted the time to peak I Na to earlier times (Fig. 6A, inset, circles) , revealing an accelerating effect on current time course. The time to peak I Na was reduced ϳ25% by 0.83 mM isoflurane (n ϭ 2). From the fit of the complete current time course, act / ctl decreased ϳ30%, whereas inact / ctl decreased ϳ95% for 0.83 mM isoflurane (n ϭ 2; Fig. 6B ). Both effects contributed to the reduction of peak I Na by isoflurane (Fig. 6B, inset) . The time to half activation was less sensitive to isoflurane than the time to peak I Na (Fig. 6A, inset) . This suggests rapid tonic block of open channels during activation before current reaches peak amplitude and/or tonic block of closed channels, which cannot be distinguished by these data.
Use-Dependent Block of NaChBac by Isoflurane. NaChBac exhibited greater use-dependent current decay at 2-versus 0.2-Hz stimulus frequency (Table 2 , upper), which reflects the slow recovery of NaChBac from inactivation. Isoflurane enhanced the use-dependent decay of I Na and increased the time constant (Table 2, lower). Isoflurane also produced tonic block evident in reduced normalized I Na amplitudes ( Fig. 7 ; Table 2 ). The enhanced use-dependent reduction of residual current, expressed as normalized I Na plateau, by isoflurane was greater from a holding potential of Ϫ80 mV (⌬C ϭ Ϫ0.31) than from Ϫ100 mV (⌬C ϭ Ϫ0.14; Table 2 ), consistent with enhanced channel inactivation and slower recovery from inactivation at a holding potential of Ϫ80 mV.
Discussion
Volatile anesthetics inhibit native neuronal and recombinant mammalian voltage-gated Na ϩ channels in a voltagedependent manner by enhanced inactivation and tonic block (Rehberg et al., 1996; Ratnakumari et al., 2000; Ouyang et al., 2003; Shiraishi and Harris, 2004; Ouyang and Hemmings, 2005) . We now show that isoflurane inhibits the prokaryotic voltage-gated Na ϩ channel NaChBac at concentrations that are comparable with those that block neuronal (Ratnakumari et al., 2000; Ouyang et al., 2003; Ouyang and Hemmings, 2005) and heterologously expressed mammalian Na ϩ channels (Rehberg et al., 1996; Stadnicka et al., 1999; Shiraishi and Harris, 2004) . The simple single-domain structure, homologous pore region, and slower gating kinetics compared with eukaryotic channels make NaChBac an ex- Fig. 4 . Effects of isoflurane on NaChBac activation. A, NaChBac conductance was calculated (see Materials and Methods) and plotted for two time points during the depolarizing pulse as shown in Fig. 1A . Peak at 10 to 20 ms and end of pulse at 29 ms. Conductance was plotted versus the 30-ms depolarizing test voltage (Ϫ60 to ϩ40 mV). B, conductance was normalized to its maximal control value and fitted to a Boltzmann equation. Mean isoflurane concentrations were 0.79 Ϯ 0.06 mM for holding potential of Ϫ80 mV and 0.82 Ϯ 0.05 mM for holding potential of Ϫ100 mV (mean Ϯ S.E.M.; n ϭ 7-8). cellent model for structure-function studies of the pharmacology and ion channel binding sites of volatile anesthetics. The similar pharmacological sensitivity to isoflurane suggests that the site(s) of volatile anesthetic interaction with voltage-gated channels is conserved from bacteria to mammals.
Isoflurane and other volatile anesthetics affect multiple molecular targets critical to neuronal signaling in addition to Na ϩ channels, in particular GABA A and glycine receptors, the principal inhibitory ligand-gated ion channels . Resolution of the relative contributions of various anesthetic-sensitive targets to the spectrum of pharmacological effects has been greatly facilitated by the design of anesthetic-insensitive mice harboring site-specific mutations in GABA A receptors identified by structure-function studies (Jurd et al., 2003) . This approach in the much larger four-domain voltage-gated ion channels will be greatly facilitated by models such as NaChBac. Although NaChBac differs in some respects from eukaryotic Na ϩ channels, elucidation of anesthetic mechanisms involving eukaryotic channels will be facilitated by looking at a simpler channel. The observations that NaChBac is inhibited by isoflurane at similar concentrations as Na v and that the mechanisms are similar to those observed for Na v validates this approach. Because NaChBac is selective for Na ϩ , it is reasonable to assume that features of the pore structure will be similar between NaChBac and other Na ϩ channels. Similarities and differ- , p Ͻ 0.001 for Ϫ80 mV holding vs. Ϫ100 mV holding by unpaired t test.
Fig. 5.
Effect of isoflurane on NaChBac inactivation. A, representative curves for steady-state inactivation before and after application of 0.78 mM isoflurane. Inactivation was measured using a two-pulse protocol in which cells were held at Ϫ80 mV and exposed to a 2-s conditioning pulse from Ϫ100 to 0 mV, followed by a 30-ms test pulse to Ϫ20 or to Ϫ10 mV to determine channel availability. B, normalized I Na was fit to a Boltzmann equation to yield voltage of 50% maximal inactivation (V 1/2in ). Isoflurane significantly shifted the voltage dependence of steady-state inactivation in the negative direction, with no effect on slope factors. Mean isoflurane concentration was 0.83 Ϯ 0.06 mM. Data expressed as mean Ϯ S.E.M. (n ϭ 5). ‫,ءءء‬ p Ͻ 0.001 by paired t test. Fig. 6 . Differential effect of isoflurane on NaChBac activation and inactivation kinetics. A, representative currents elicited by pulses to Ϫ20 mV from a holding potential of Ϫ100 mV. Superimposed on each trace (in gray) is the fit of the current data to at ASPET Journals on July 7, 2017 jpet.aspetjournals.org ences between the mechanisms of block of NaChBac relative to other Na ϩ channel blockers will be informative in understanding the pharmacology of both channel types. Because NaChBac is presumed to be a homotetramer (by analogy with K ϩ channels), it is easier to mutate regions of interest for structure-function studies in this smaller protein than it is with the eukaryotic Na ϩ channels (Zhao et al., 2004) . NaChBac can also be expressed in bacteria; hence, large amounts of the protein can be produced that will facilitate finer structural studies. NaChBac expresses well in mammalian cells so mutants can be easily tested.
The effect of isoflurane on NaChBac activation differs from its effects on mammalian Na v (Rehberg et al., 1996; Stadnicka et al., 1999; Ouyang et al., 2003; Shiraishi and Harris, 2004) , which exhibit no change in channel activation kinetics or activation curves. The rising and falling faces of NaChBac currents could be reproduced reasonably well using a Hodgkin-Huxley m 3 h kinetic model for classical nerve type Na ϩ channels (Hodgkin and Huxley 1952) , even though some nerve-type Na ϩ channels are not fit well by the m 3 h kinetic model (Herzog et al., 2001) . Although m 3 h kinetics do not accurately describe the activation time course because of transitions between multiple closed states before channel opening in neuronal Na ϩ channels (Baranauskas and Martina, 2006) that are also present in NaChBac (Kuzmenkin et al., 2004) , the m 3 h model allows a simple phenomenological comparison of relative effects on activation and inactivation. Although a change in activation kinetics was apparent, it was not as large as the speeding of inactivation. However, a significant shift in the voltage dependence of activation and of inactivation was observed. Because NaChBac activates ϳ6-fold slower than mammalian Na v (Ren et al., 2001) , the mechanism of tonic block of NaChBac by isoflurane might differ from its effects on mammalian Na v by a greater contribution of open channel block during activation. Analysis of the mechanisms underlying isoflurane effects on NaChBac activation will require detailed gating current and single channel studies.
Isoflurane dissociates quickly from mammalian Na ϩ channels, which require rapid repetitive depolarization to develop use-dependent block (unpublished observations). The slower inactivation of NaChBac compared with Na v resulted in enhanced use-dependent block by isoflurane at relatively lowstimulus frequency. These results are consistent with the modulated receptor hypothesis of Na ϩ channel block (Hille, 1977; Hondeghem and Katzung, 1977) in which the inactivated state is selectively stabilized by isoflurane. Open channel block by isoflurane is also probably due to the slower activation and inactivation kinetics of NaChBac. The NaChBac tail current was inhibited by isoflurane, and the tail conductance ratio overlapped with the pseudo steady-state conductance ratio, suggesting that enhancement of inactivation is the predominant mechanism of isoflurane inhibition. More detailed mechanistic analysis of the mechanisms of isoflurane block will require more refined gating and single-channel studies.
In current models of Na v gating, the S4 helix, which contains highly conserved positively charged amino acids, plays a critical role as voltage sensor for activation (Chahine et al., 2004) . Similar to Na v , NaChBac undergoes several gating transitions involving gating charge movement (Kuzmenkin et al., 2004) , the kinetics of which closely follow those of , p Ͻ 0.001 for Ϫ100 mV holding vs. Ϫ80 mV holding by unpaired t test.
Fig. 7.
Use-dependent block of NaChBac by isoflurane. Isoflurane increased use-dependent decay of I Na more from a holding potential of Ϫ80 mV (left) than from Ϫ100 mV (right). Graphs show that peak amplitude of each pulse normalized to that of the first pulse (mean Ϯ S.E.M.; n ϭ 6 -11), plotted against stimulus number, and fitted to a monoexponential function (see Materials and Methods). Protocol: 30 ms, 2-Hz test pulses from holding potential (Ϫ80 or Ϫ100 mV) to peak activation voltage (Ϫ20 to 0 mV) in 10-mV steps.
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at ASPET Journals on July 7, 2017 jpet.aspetjournals.org macroscopic activation. A neutralizing mutation in S4 (R114C) produced similar effects on NaChBac as isoflurane: a positive shift in the voltage dependence of activation and a negative shift in voltage dependence of inactivation (Chahine et al., 2004) . The positive shift in the voltage dependence of NaChBac activation and the net decrease in channel conductance by isoflurane suggest a reduction in voltage sensitivity via direct or indirect interaction with the voltage sensor. Because there are no interdomain linkers and the N terminus of NaChBac is too short to achieve N-type tethered ball-chain inactivation, NaChBac is predicted to undergo Ctype inactivation (Catterall, 2001; Ren et al., 2001 ) similar to slow inactivation in Na v (Balser et al., 1996a; Fukuda et al., 2005) and K v channels (López-Barneo et al., 1993; CorderoMorales et al., 2006) . This was confirmed by a recent report in which the pore S6 linker was found to be important in NaChBac inactivation (Pavlov et al., 2005) . Our results indicate that NaChBac availability was reduced by isoflurane, evident in the negative shift in the inactivation curve as well as marked enhancement of current decay upon opening. The slope factor for inactivation was unaffected, consistent with no effect of isoflurane on the voltage sensor during channel inactivation. Because NaChBac lacks fast inactivation as seen in Na v , use-dependent block is probably more complicated in Na v with additional coupling between channel closing and recovery. There are similarities between the effects of isoflurane and local anesthetics on Na v . Voltage-dependent block by isoflurane of NaChBac (this study) and of Na v (Stadnicka et al., 1999; Ouyang et al., 2003; Ouyang and Hemmings, 2005) is consistent with greater anesthetic affinity for the inactivated state, similar to local anesthetic and anticonvulsant block of Na v (Ragsdale et al., 1994; Nau and Wang, 2004) . Multiple state-dependent mechanisms are involved in local anesthetic block. Lidocaine slows gating transitions during activation (Vedantham and Cannon, 1999; Wang et al., 2004) , allosterically modifies S4 of domains III and IV (Sheets and Hanck, 2003) , and interacts with the extracellular loop of domain IV (E1555; Li et al., 2002) and with the S4 voltage sensor (Hanck et al., 2000; Sheets and Hanck, 2003) . These findings and our observation that isoflurane shifts NaChBac activation indicate that isoflurane, similar to local anesthetics, acts via multiple mechanisms to affect channel gating. The outer pore vestibule is a pivotal determinant of local anesthetic binding in Na v such that the W1531C mutation in domain IV of Na v 1.4 eliminates local anesthetic block (Li et al., 2002; Tsang et al., 2005) . Similar target sites for volatile anesthetics could exist in the NaChBac pore region and should be identifiable by site-directed mutagenesis.
Upon prolonged depolarization, mammalian Na v channels open, and they subsequently enter fast and slow inactivated states (Hille, 2001; Nau and Wang, 2004) . The mechanism of slow inactivation differs from that of fast inactivation by involving rearrangement of the selectivity filter (Balser et al., 1996a; Hille, 2001) , as seen in C-type inactivation of K v channels (López-Barneo et al., 1993; Cordero-Morales et al., 2006) . According to the modulated receptor model (Hille, 1977; Hondeghem and Katzung, 1977) , use-dependent block during repetitive stimulation results from accumulation of fast-inactivated channels and slowed recovery of channel availability from mostly fast inactivation. Local anesthetics also produce use-dependent block by modulating slow inactivation (Balser et al., 1996b; Vedantham and Cannon, 1999; Fukuda et al., 2005) and/or inhibiting activation (Vedantham and Cannon, 1999; Wang et al., 2004) . Because the inactivation kinetics of NaChBac resembles C-type inactivation of K v channels and slow inactivation of Na v channels, isoflurane might also reduce Na v availability via effects on activation and inactivation (enhancing inactivation and delaying recovery). The relative contribution of fast and slow inactivation to block of Na v by isoflurane is an interesting area for further investigation. Structure-function studies to compare volatile anesthetic effects on NaChBac and Na v channels should provide a useful approach in dissecting the mechanisms of anesthetic modulation of voltage-gated Na ϩ channels.
